Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas. It really is the beachhead many read across sort of result” given the company’s pharmaceuticals and medical device businesses.
Last year company also predicted to provide an updated full year outlook after its $1.7 billion acquisition of the wave, which develops a number of treatments for heart failure with just a few minutes left to the closing bell on Wall Street.Joining us now, Chris Shibutani Goldman Sachs, senior biotechnology analyst in global investment research, Chris, it's great to see you here.
The company has been exposed to a bit of an overhang related to long standing litigation concerns to related injury claims.We would argue that they're probably approaching towards the later innings and if we can get some clarity on the resolution, that would be very reassuring for investors. Um, the company has already been sort of embarking on a, I guess you would call it a turnaround project for itself.Yeah, I think when you look at stock performance for Pfizer, it naturally peaked several years back at the height of the pandemic where the contributions the company made to address the COVID pandemic with a vaccine and the therapeutic packs of it were certainly tremendous.
I do think that attention to some of these issues does heighten the level of urgency and that's probably not a bad thing anytime the company is trying to address some of the challenges, Chris, always great to see you and have you on the show.On Friday in Colorado, former President Donald Trump announced 'Operation Aurora' a plan that invokes the Alien Enemies Act of 1798.